View in EDS HTML Full Text PDF Full Text

Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.

Saved in:
Bibliographic Details
Title: Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
Authors: Jain P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kanagal-Shamanna R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang S; Department of Hemato-pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ok CY; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Navsaria L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nastoupil L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lee HJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tang G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yin CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Badillo M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Li S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel KM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Flowers C; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vega F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang L; Department of Hemato-pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang ML; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Source: American journal of hematology [Am J Hematol] 2021 May 01; Vol. 96 (5), pp. E137-E140. Date of Electronic Publication: 2021 Feb 11.
Publication Type: Letter
Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33491779
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jain+P%22">Jain P</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Kanagal-Shamanna+R%22">Kanagal-Shamanna R</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Zhang+S%22">Zhang S</searchLink>; Department of Hemato-pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Ok+CY%22">Ok CY</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Navsaria+L%22">Navsaria L</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Nastoupil+L%22">Nastoupil L</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Lee+HJ%22">Lee HJ</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Tang+G%22">Tang G</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Yin+CC%22">Yin CC</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Badillo+M%22">Badillo M</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Nair+R%22">Nair R</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Li+S%22">Li S</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Patel+KM%22">Patel KM</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Flowers+C%22">Flowers C</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Vega+F%22">Vega F</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Wang+L%22">Wang L</searchLink>; Department of Hemato-pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Wang+ML%22">Wang ML</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227610369%22">American journal of hematology</searchLink> [Am J Hematol] 2021 May 01; Vol. 96 (5), pp. E137-E140. <i>Date of Electronic Publication: </i>2021 Feb 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7610369 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1096-8652 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203618609%22">03618609 </searchLink><i>NLM ISO Abbreviation: </i>Am J Hematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33491779
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/ajh.26109
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: E137
    Titles:
      – TitleFull: Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jain P
      – PersonEntity:
          Name:
            NameFull: Kanagal-Shamanna R
      – PersonEntity:
          Name:
            NameFull: Zhang S
      – PersonEntity:
          Name:
            NameFull: Ok CY
      – PersonEntity:
          Name:
            NameFull: Navsaria L
      – PersonEntity:
          Name:
            NameFull: Nastoupil L
      – PersonEntity:
          Name:
            NameFull: Lee HJ
      – PersonEntity:
          Name:
            NameFull: Tang G
      – PersonEntity:
          Name:
            NameFull: Yin CC
      – PersonEntity:
          Name:
            NameFull: Badillo M
      – PersonEntity:
          Name:
            NameFull: Nair R
      – PersonEntity:
          Name:
            NameFull: Li S
      – PersonEntity:
          Name:
            NameFull: Patel KM
      – PersonEntity:
          Name:
            NameFull: Flowers C
      – PersonEntity:
          Name:
            NameFull: Vega F
      – PersonEntity:
          Name:
            NameFull: Wang L
      – PersonEntity:
          Name:
            NameFull: Wang ML
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2021 May 01
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1096-8652
          Numbering:
            – Type: volume
              Value: 96
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: American journal of hematology
              Type: main
ResultId 1